The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361). The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined. There were no clinically relevant differences in glycated haemoglobin (HbA1c) changes among the three subgroups in the dulaglutide group; in the glargine group, a numerically greater reduction was observed in combination with BG alone compared to the other two groups (SU alone and SU + BG). Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG. The incidence of adverse events among subgroups was significantly different in the glargine group but not in the dulaglutide group. Incidence of hypoglycaemia was highest in combination with SU for both treatments.
The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361). The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined. There were no clinically relevant differences in glycated haemoglobin (HbA1c) changes among the three subgroups in the dulaglutide group; in the glargine group, a numerically greater reduction was observed in combination with BG alone compared to the other two groups (SU alone and SU + BG). Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG. The incidence of adverse events among subgroups was significantly different in the glargine group but not in the dulaglutide group. Incidence of hypoglycaemia was highest in combination with SU for both treatments.
For patients with T2D, dulaglutide added to concomitant BG may be more likely to result in weight loss than dulaglutide added to concomitant SU.
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| INTRODUCTION
Dulaglutide is a long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist that mimics some of the effects of endogenous GLP-1. 1 In randomized phase III studies in Japan, once-weekly dulaglutide 0.75 mg (dulaglutide) has shown superiority to placebo and insulin glargine (glargine) and non-inferiority to once-daily liraglutide 0.9 mg in glycated haemoglobin (HbA1c) changes. 2 | METHODS
| Study design and patients
The study was a 26-week, phase III, randomized, open-label, noninferiority study comparing the efficacy and safety of once-weekly dulaglutide 0.75 mg with once-daily glargine in Japanese patients with T2D inadequately controlled with monotherapy (SU or BG) or dual therapy (SU and BG). 3 Analysis methods are described in File S1, Supporting Information. Some of the OHA subgroup analyses reported here were prespecified in the study analysis plan, while others were post hoc. There was no adjustment for multiplicity.
3 | RESULTS
| Patient characteristics
Demographics for all 361 patients, according to treatment and OHA subgroup, are presented in Table S1 , Supporting Information. The majority of patients (71%) were male. Mean age was 57 years, mean weight was 71 kg, and mean body mass index (BMI) was 26.0 kg/m 2 . 
| Efficacy
In the dulaglutide group, mean changes from baseline in HbA1c after 26 weeks ranged from −1.37% (−15.0 mmol/mol) (SU + BG) to −1.48% (−16.2 mmol/mol) (BG alone and SU alone); in the glargine group, mean changes ranged from −0.78% (−8.5 mmol/mol) (SU) to −1.02% (−11.2 mmol/mol) (BG) ( Figure 1A ). In all three subgroups, dulaglutide reduced HbA1c significantly compared to glargine (p < .001, all). There were no statistically significant differences in HbA1c changes among the subgroups (BG vs. SU, BG vs. SU + BG, SU vs. SU + BG) in either treatment group (p ≥ .069, all).
In the dulaglutide group, patients receiving BG or SU + BG lost weight at week 26 on average, while patients receiving SU gained weight; in the glargine group, patients in all three OHA subgroups gained weight on average ( Figure 1B ). In the BG and SU + BG subgroups, dulaglutide significantly reduced weight compared to glargine (p < .001, both); in the SU subgroup, weight increase in the dulaglutide group was significantly less than that in the glargine group (p = .041). In the dulaglutide group, weight change was significantly different between the SU subgroup and the BG subgroup (p = .013);
there were no other statistically significant differences in pairwise comparisons of changes in weight between the OHA subgroups within either treatment group (all other p ≥ .089). 
| Safety

| DISCUSSION
A subgroup analysis using pooled data from the three Japanese phase III studies of dulaglutide 0.75 mg has been reported previously. 5 In that analysis, use of concomitant SU and use of concomitant BG were two of the baseline characteristics evaluated. Higher incidence of hypoglycaemia was observed with dulaglutide in combination with SU, and greater weight reduction was observed in combination with BG. However, it was difficult to evaluate the pure influence of SU or BG because 33% of patients receiving SU and 40% of patients receiving BG were treated with both drugs, and the comparator arms in the studies were not included in the analyses. Therefore, in this analysis, The subgroup analyses reported here had potential limitations.
First, the results of this analysis should be interpreted with caution with respect to the OHA subgroups, as the OHAs were background therapies and were not assigned to patients randomly. Also, because the once-weekly dulaglutide dose of 0.75 mg used in Japan 9 is lower than the once-weekly 1.5 mg dose typically used in Western countries, 10,11 these results may not be generalizable in other populations. Further, these were exploratory, primarily post hoc analyses, so the sample size may not be enough to detect differences between the OHA subgroups. In addition, there were no multiplicity adjustments for the statistical tests. Finally, analyses of efficacy parameters (HbA1c and weight) adjusted for potential confounding factors (baseline values and BMI group), but analyses of safety parameters (hypoglycaemia and adverse events) did not.
In conclusion, once-weekly dulaglutide 0.75 mg improved blood glucose control (compared to baseline and compared to glargine) as measured by HbA1c after 26 weeks regardless of concomitant OHA (SU, BG or SU + BG). Dulaglutide in combination with BG alone resulted in weight loss and lower incidence of hypoglycaemia compared to dulaglutide in combination with SU. For patients with T2D, dulaglutide in addition to concomitant BG may be more likely to result in weight loss than dulaglutide in addition to concomitant SU.
